Abstract: Objective To investigate the therapeutic effect of magnesium isoglycyrrhizinate combined with hybrid blood purification in patients with severe acute pancreatitis (SAP), and its impacts on inflammatory indicators and prognosis.  Methods  A total of 102 SAP patients admitted to the First Affiliated Hospital of Henan University of Science and Technology were selected and randomly divided into two groups: the monotherapy group (n=51) and the combination  group (n=51). The monotherapy group received hybrid blood purification alone, while the combination group received magnesium isoglycyrrhizinate in addition to hybrid blood purification. The following outcomes were compared between the two groups: total effective rate, time to symptom relief, laboratory biochemical indicators, serum inflammatory markers, prognosis, and adverse reactions.  Results  The combination group showed a significantly higher overall effective rate (94.12%) compared with the monotherapy group (80.39%) (χ2=4.320, P=0.038). Additionally, the combination group had significantly shorter times to pain relief, nausea and vomiting relief, and hospitalization (t=9.112, t=13.679, t=6.537, all P＜0.001). The following indicators were significantly lower in the combination group than in the monotherapy group:  Acute Physiology And Chronic Health Evaluation II (APACHE II) score, C-reactive protein (CRP), amylase (AMS), interleukin-8 (IL-8), and high mobility group protein 1 (HMGB1) levels (t=5.386, t=15.051, t=12.850, t=12.312, t=13.771, all P＜0.001). There was no significant difference in the incidence of adverse reactions such as edema and rash between the two groups (χ2=0.917, P=0.338).  Conclusion  The combination of magnesium isoglycyrrhizinate and hybrid blood purification in SAP patients can effectively reduce inflammatory injury, shorten hospitalization time.

Key words: Severe acute pancreatitis, Magnesium isoglycyrrhizinate, Hybrid blood purification, Inflammatory factors, Untoward reactions